Piramal Pharma Ltd

Stage 2 · Advancing · week 12Setup 4.5 WatchSolid +0.8

As of 9 Oct 2026, Piramal Pharma is in Stage 2 — advancing, the uptrend phase, in week 12 (since 16 Jul 2026). It closed at ₹197, 13.1% below its 52-week high and above its 200-day average, which is rising. In Health Care, 44.6% of stocks are in Stage 2.

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. More about the company

₹196.9
+0.23% today
₹26,087 Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dPharmaceuticals 51.3%-0.4 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

4.5 Watch

Momentum

Steady

Edge

Solid +0.8

Setup-score rank among Stage 2 peers: #39 of 61 in Pharmaceuticals · #47 of 78 in Health Care

Is PPLPHARMA early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-13.1%
₹133.3 lo₹226.6 hi
13.1% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 12
1w13w26w
Week 12 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
12.5%
200 DMA: ₹175.1 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.29x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -3.4% vs MA50 +5.4%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-13.1%
3M
+11.1%
6M
+36.9%
YTD
+10.6%
1Y
-1.1%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
This stock ranks #56 of 74 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
→ Flat
Stage 2%
51.3%
20d Δ
-0.4pp
1M return
-4.2%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #44 of 58 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-14 → 2026-10-09
S2 18w
S2 38w
S4 20w
S4 23w
2023-07-142026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 4w → S1 2w → S2 8w → S3 3w → S2 18w → S3 7w → S2 38w → S3 9w → S4 7w → S1 3w → S4 20w → S1 4w → S4 23w → S1 9w → S2 12w current
Total tracked: 168 weeks across 15 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-07-16
2 appearances in last 60 days. First seen: 2024-05-03.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S2
Wk 12 · Vol 0.29x
2026-10-08S2
Wk 12 · Vol 0.38x
2026-10-07S2
Wk 12 · Vol 0.44x
2026-10-06S2
Wk 12 · Vol 0.33x
2026-10-05S2
Wk 12 · Vol 0.35x
2026-10-01S2
Wk 11 · Vol 0.65x
2026-09-30S2
Wk 11 · Vol 0.39x
2026-09-29S2
Wk 11 · Vol 0.89x
2026-09-28S2
Wk 11 · Vol 0.46x
2026-09-25S2
Wk 11 · Vol 0.58x
2026-09-24S2
Wk 10 · Vol 0.76x
2026-09-23S2
Wk 10 · Vol 0.50x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
RPGLIFE
wk 16 · -12.0% from hi
7.6
Moving averages & range
50 DMA
₹208.8
200 DMA
₹175.1
52W High
₹226.6
52W Low
₹133.3
5D Low
₹194.9
Resistance levels (recent highs)
20d High
₹214.7
60d High
₹226.6
120d High
₹226.6
250d High
₹226.6
Next resistance
+9.1%
to 20d High
Ask the Market AI about PPLPHARMAAsk →
ROE
-4.0%
Profit margin -3.7%
Dividend Yield
0.08%
P/B 2.9
About this companyHealth Care· Pharmaceuticals

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.